FindTrial
Sign In

Blood testing to predict good response to chemotherapy

Assessment of serum tumor markers in response to neoadjuvant chemotherapy in locally advanced triple negative breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/10/028763
Enrollment
100
Registered
2020-10-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with a diagnosis of locally advanced triple negative breast cancer IRCH

Exclusion criteria

Exclusion criteria: Not giving informed consent

Design outcomes

Primary

MeasureTime frame
To determine the decline of serum tumor markers (CA-15.3, CA 27.29, CEA, CA 125, cathepsin D) with neoadjuvant chemotherapyTimepoint: Baseline, 12 weeks, 24 weeks, 30 weeks—

Secondary

MeasureTime frame
a) To correlate the decline of serum tumor markers with pathological complete response b) To assess the decline in serum tumor markers after surgery Timepoint: Baseline, 12 weeks, 24 weeks, 30 weeks—

Countries

India

Contacts

Public ContactAtul Batra

AIIMS, New Delhi

batraatul85@gmail.com01129575232

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026